CSL has been given marketing authorisation from the European Commission for Privigen, a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended.
Privigen is a human immunoglobulin therapy that can be used to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended.
Cases of measles have been rising in Europe since 2023. Health authorities across Europe, including the European Centre for Disease Prevention and Control, reported a sharp increase in measles cases in 2024. In 2025, case numbers remained elevated, with reported infections approximately twice as high as in 2023.
Emmanuelle Lecomte Brisset, Head of Global Regulatory Affairs and Safety at CSL, said: “While vaccination remains the most effective way to prevent measles, outbreaks across Europe highlight the urgent need for additional tools to protect those at risk. This approval ensures clinicians have access to an immunoglobulin option where passive protection may be considered.”
Privigen has been authorised for use in susceptible high-risk individuals, including immunocompromised patients, pregnant women without evidence of immunity, and infants or other vulnerable contacts with high unmet needs.
It has a well-established safety profile based on clinical use and long-term real-world experience with immunoglobulin therapies.
Immunoglobulin therapy works by providing concentrated antibodies that can neutralise the measles virus after exposure and may provide passive antibody protection following exposure. This makes immunoglobulin therapy a potential option for individuals who cannot rely on vaccination or require prompt prophylactic support following exposure.
European approval is based on strong clinical and real-world evidence supporting the safety and efficacy of Privigen for the approved use in preventing measles and protecting high-risk patients.